Therapeutically Comparable. Operationally Complex.
Drugs therapeutically similar and approved through the 505(b)(2) pathway can be especially valuable to community oncology. They can speed up the availability of enhanced formulations of familiar drugs, potentially reduce shortages, and help contain costs. However, with recent federal coding changes and operational challenges, optimizing their use can be a complex moving target. Our white paper, authored by Derek Burns, PharmD, MBA, BCPS, BCSCP, CLP, provides best practices to help you navigate these complexities and stay ahead. Get your copy today.
What you’ll learn:
- How the 505(b)(2) pathway works: Find out how this pathway accelerates drug development and how recent billing code changes affect oncology practices.
- Business insights: Discover how 505(b)(2) generics can make drug preparation and administration more convenient and cost-effective.
- Operational strategies: Learn about seven key questions that will help you manage inventory, billing, and clinical differences.
- Injectable and oral options: Explore both injectable and oral 505(b)(2) drugs and their role in oncology practices.
- Best practices for success: Get tips on conducting quarterly reviews, appointing a subject matter expert, and staying updated on coding and pricing changes.
Get your copy today
Learn about the full potential of 505(b)(2) drugs in your oncology practice. Fill out the form below to download the complete white paper and start optimizing your operational strategies now.
Solution Highlight
Business and Pharmacy Advisory Services
Customized consulting solutions designed to help your specialty practice operate with efficiency, achieve financial health, and drive clinical excellence.